SELLAS Life Sciences Boosts Executive Severance, Change-of-Control Payouts
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS Life Sciences Group has amended the severance and change-of-control agreements for its CEO, CFO, and CDO, effective June 24, 2026. This follows an 8-K filing earlier today disclosing these changes. The amendments include providing certain change-in-control severance payments to the CEO in a lump sum, and for the CFO and CDO, enhanced change-of-control benefits now include 15 months of salary, target bonus, COBRA for up to 18 months, and immediate vesting. These updates, reportedly due to market and competitive review, could increase potential costs in a change of control event and are relevant for executive retention.
At the time of this announcement, SLS was trading at $9.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $1.39 to $9.51. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.